Using NHANES data, researchers estimated the prevalence of chronic axial pain, inflammatory back pain, axial spondyloarthritis, and peripheral arthritis in inflammatory bowel disease.
A team of researchers from Japan studied the presence of Sjögren syndrome among patients with anticentromere antibodies.
Posimir is a novel formulation of bupivacaine, an amide local anesthetic, designed to be administered directly into the surgical site.
The ongoing phase 3 BE MOBILE 2 study compared the efficacy and safety of bimekizumab to placebo in 332 adults with active ankylosing spondylitis.
The approval was based on data from a phase 3 study which evaluated tofacitinib in adults with active AS who had an inadequate response to at least 2 NSAIDs.
The approval was based on data from the phase 2/3 SELECT-AXIS 1 and the phase 3 SELECT-AXIS 2 trials.
A EULAR task force recently developed recommendations for the management of cardiovascular risk in patients with rheumatic and musculoskeletal diseases, including gout, lupus, and systemic sclerosis.
The approval was based on data from the 2-year phase 3 JUNIPERA study that evaluated secukinumab in pediatric patients aged 2 to 17 years with a confirmed diagnosis of ERA or JPsA.
The approval was based on a comprehensive data package demonstrating that Yusimry was highly similar to the reference product, Humira.
Shortly after an EUA was issued, Genentech announced that tocilizumab (marketed under the brand name Actemra) was in shortage.
